{"id":7485,"date":"2024-12-18T06:01:50","date_gmt":"2024-12-18T14:01:50","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7485"},"modified":"2024-12-18T06:07:43","modified_gmt":"2024-12-18T14:07:43","slug":"highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/","title":{"rendered":"HighField Biopharmaceuticals \u5728\u4e2d\u56fd\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\uff0c\u7528\u4e8e\u5176\u72ec\u7279\u7684 TRAFsomeTM T \u7ec6\u80de\u63a5\u5408\u5242 (HF50) \u6cbb\u7597\u5b9e\u4f53\u80bf\u7624"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

2024 \u5e74 12 \u6708 18 \u65e5 | HighField Bio \u65b0\u95fb\u7a3f<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

HighField Biopharmaceuticals \u5728\u4e2d\u56fd\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u8bb8\u53ef\uff0c\u7528\u4e8e\u5176\u72ec\u7279\u7684 TRAFsomeTM T \u7ec6\u80de\u63a5\u5408\u5242 (HF50) \u6cbb\u7597\u5b9e\u4f53\u80bf\u7624<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

HF50 \u7684 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30\u5176\u5728\u665a\u671f\u5b9e\u4f53\u80bf\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u5f81\u3001\u514d\u75ab\u539f\u6027\u548c\u521d\u6b65\u7597\u6548<\/i>\u00a0\u9884\u8ba1\u5c06\u4e8e 2025 \u5e74\u7b2c\u4e00\u5b63\u5ea6\u5f00\u59cb\u3002<\/i><\/strong><\/p>

HF50 \u662f\u7a81\u7834\u6027\u7684\u514d\u75ab\u8102\u8d28\u4f53\u5e73\u53f0\u7684\u4e00\u90e8\u5206\uff0c\u8be5\u5e73\u53f0\u53ef\u6fc0\u6d3b\u548c\u5f15\u5bfc T \u7ec6\u80de\u5e76\u914d\u5907\u4e0d\u540c\u7684\u6709\u6548\u8f7d\u8377\uff0c\u4ece\u800c\u521b\u9020\u51fa\u4e00\u79cd\u5b8c\u5168\u4e0d\u540c\u7684\u65b9\u6cd5\u6765\u8c03\u52a8\u514d\u75ab\u7cfb\u7edf\u6cbb\u7597\u591a\u79cd\u75be\u75c5\u3002<\/i><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u4e2d\u56fd\u676d\u5dde\u2014\u20142024 \u5e74 12 \u6708 17 \u65e5\u2014\u2014HighField Biopharmaceuticals \u662f\u4e00\u5bb6\u4f7f\u7528\u8102\u8d28\u7597\u6cd5\u6cbb\u7597\u764c\u75c7\u3001\u7cd6\u5c3f\u75c5\u548c\u5176\u4ed6\u75be\u75c5\u7684\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u4eca\u5929\u5ba3\u5e03\uff0c\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3\u5df2\u6279\u51c6\u8be5\u516c\u53f8\u7684\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c (IND) \u7533\u8bf7\uff0c\u5f00\u59cb\u5bf9\u665a\u671f\u5b9e\u4f53\u7624\u764c\u75c7\u60a3\u8005\u8fdb\u884c HF50 \u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>

HighField \u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba Yuhong Xu \u535a\u58eb\u8868\u793a\uff1a\u201c\u8fd9\u5bf9\u6211\u4eec\u516c\u53f8\u548c\u60a3\u8005\u6765\u8bf4\u90fd\u662f\u4e00\u4e2a\u975e\u5e38\u91cd\u8981\u7684\u91cc\u7a0b\u7891\u3002HF50 \u662f\u4e00\u79cd T \u7ec6\u80de\u91cd\u5b9a\u5411\u6297\u4f53\u7247\u6bb5\u951a\u5b9a\u8102\u8d28\u4f53\uff08TRAFsome\uff09\uff0c\u9644\u7740\u4e24\u79cd\u4e0d\u540c\u7684\u6297\u4f53\uff1b\u7b2c\u4e00\u79cd\u6297\u4f53\u4e0e T \u7ec6\u80de\u7ed3\u5408\uff0c\u7b2c\u4e8c\u79cd\u6297\u4f53\u4e0e\u80bf\u7624\u7ec6\u80de\u7ed3\u5408\u3002\u8fd9\u662f\u6211\u4eec\u514d\u75ab\u8102\u8d28\u4f53\u5e73\u53f0\u63a8\u51fa\u7684\u9996\u6b3e\u8102\u8d28\u4f53 T \u7ec6\u80de\u63a5\u5408\u5242\uff0c\u4e5f\u662f\u7b2c\u4e00\u4e2a\u8fdb\u5165\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4ea7\u54c1\u3002\u201d<\/p>

HF50\u9664\u4e86\u5c06T\u7ec6\u80de\u8f6c\u5316\u4e3a\u764c\u75c7\u6d88\u706d\u8005\u5927\u519b\u4e4b\u5916\uff0c\u8fd8\u643a\u5e26\u5728\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u91ca\u653e\u7684\u6709\u6548\u8f7d\u8377\uff0c\u4ee5\u4fc3\u8fdb\u6297\u80bf\u7624\u514d\u75ab\u53cd\u5e94\u3002<\/p>

TRAFsome T \u7ec6\u80de\u63a5\u5408\u5668\u7684\u8bbe\u8ba1\u5efa\u7acb\u5728 HighField \u7684 LipoADCplex \u7684\u6210\u529f\u57fa\u7840\u4e4b\u4e0a\u5546\u6807<\/sup>\u00a0\u5e73\u53f0\u3002\u8be5\u5e73\u53f0\u7684\u9996\u6b3e\u4ea7\u54c1\u662f K1\uff0c\u5b83\u542b\u6709\u6297 HER2 \u6297\u4f53\uff0c\u53ef\u4e0e\u80bf\u7624\u7ec6\u80de\u7ed3\u5408\u5e76\u9012\u9001\u6297\u764c\u836f\u7269\u3002K1 \u6b63\u5728\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u5df2\u5728\u764c\u75c7\u60a3\u8005\u4e2d\u663e\u793a\u51fa\u975e\u5e38\u597d\u7684\u5b89\u5168\u6027\u3002<\/p>

\u201c\u4e00\u65e6\u6211\u4eec\u8bc1\u660e\u4e86 LipoADCplex\u5546\u6807<\/sup>\u00a0\u201cT \u7ec6\u80de\u63a5\u5408\u5242\u53ef\u80fd\u6bd4 ADC\uff08\u6297\u4f53-\u836f\u7269\u5076\u8054\u7269\uff09\u66f4\u5b89\u5168\u3001\u66f4\u4fbf\u5b9c\u3001\u66f4\u6709\u6548\uff0c\u4e0b\u4e00\u6b65\u5c31\u662f\u7528\u7b2c\u4e8c\u79cd\u6297\u4f53\u6765\u6fc0\u6d3b\u514d\u75ab\u7ec6\u80de\uff0c\u4ece\u800c\u5bf9\u9776\u7ec6\u80de\u8fdb\u884c\u514d\u75ab\u6cbb\u7597\uff0c\u201d\u5f90\u535a\u58eb\u89e3\u91ca\u9053\u3002\u201cT \u7ec6\u80de\u63a5\u5408\u5242\u53ef\u80fd\u975e\u5e38\u6709\u6548\u3002\u4f46\u8fc7\u5ea6\u523a\u6fc0\u53ef\u80fd\u4f1a\u5bfc\u81f4\u6bd2\u6027\u548c T \u7ec6\u80de\u8870\u7aed\u7684\u9ad8\u98ce\u9669\u3002\u201d<\/p>

HF50\u76841\u671f\u5f00\u653e\u6807\u7b7e\u3001\u5242\u91cf\u9012\u589e\u548c\u5242\u91cf\u6269\u5c55\u8bd5\u9a8c\u5c06\u8bc4\u4f30\u5176\u5728\u665a\u671f\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u5f81\u3001\u514d\u75ab\u539f\u6027\u548c\u521d\u6b65\u7597\u6548\u3002\u8be5\u8bd5\u9a8c\u9884\u8ba1\u5c06\u4e8e2025\u5e741\u5b63\u5ea6\u5f00\u59cb\u3002<\/p>

\u201c\u4f5c\u4e3a T \u7ec6\u80de\u63a5\u5408\u5242\uff0cHF50 \u6bd4\u53cc\u7279\u5f02\u6027\u6297\u4f53\u6784\u5efa\u4f53\u751a\u81f3 CAR-T \u7ec6\u80de\u90fd\u66f4\u5177\u4f18\u52bf\uff0c\u201d\u5f90\u535a\u58eb\u8bf4\u9053\u3002\u201c\u8102\u8d28\u4f53 T \u7ec6\u80de\u63a5\u5408\u5242\u53ef\u4ee5\u6574\u5408\u4e09\u79cd\u7279\u5b9a\u6d3b\u6027\u3002\u7b2c\u4e00\u662f\u6fc0\u6d3b T \u7ec6\u80de\uff1b\u7b2c\u4e8c\u662f\u5c06 T \u7ec6\u80de\u5f15\u5bfc\u81f3\u9776\u7ec6\u80de\uff1b\u7b2c\u4e09\u662f\u91ca\u653e\u6709\u6548\u8f7d\u8377\u4ee5\u4fc3\u8fdb\u514d\u75ab\u53cd\u5e94\u3002\u201d<\/p>

\u5f90\u535a\u58eb\u8865\u5145\u9053\uff1a\u201cTRAFsomes \u53ef\u4ee5\u6a21\u5757\u5316\u751f\u4ea7\uff0c\u6210\u672c\u4f4e\u5ec9\u3002\u4e34\u5e8a\u524d\u6570\u636e\u8868\u660e\u5b83\u4eec\u66f4\u5b89\u5168\u3001\u66f4\u6709\u6548\u3002\u6211\u4eec\u8fd8\u53ef\u4ee5\u6dfb\u52a0\u4e0d\u540c\u7684\u6709\u6548\u8f7d\u8377\uff0c\u4ee5\u6269\u5927\u5176\u5bf9\u5176\u4ed6\u75be\u75c5\u7684\u5e94\u7528\uff0c\u5982\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u548c\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u3002\u201d<\/p>

\u5173\u4e8e HighField \u751f\u7269\u5236\u836f<\/b><\/p>

HighField \u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u9488\u5bf9\u514d\u75ab\u80bf\u7624\u5b66\u548c\u57fa\u56e0\u6cbb\u7597\u7684\u8102\u8d28\u4f53\u7ed3\u6784\u7684\u65b0\u5e94\u7528\u3002HighField \u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u4e3b\u5bfc\u4ea7\u54c1\u662f K1\uff0c\u6e90\u81ea\u5176 LipoADCplex\u5546\u6807<\/sup>\u00a0\u5e73\u53f0\uff0c\u968f\u540e\u662f HF50\uff0c\u6e90\u81ea\u5176 TRAFsome\u5546\u6807\u00a0<\/sup>\u5e73\u53f0\u3002\u8be5\u516c\u53f8\u7684\u4ea7\u54c1\u7ebf\u8fd8\u5305\u62ec K16\uff0c\u4e00\u79cd\u836f\u7269\u5305\u88f9\u7684\u514d\u75ab\u8c03\u8282\u8102\u8d28\u4f53\u9776\u5411\u00a0<\/i>\u9ad3\u7cfb\u6291\u5236\u7ec6\u80de\u00a0<\/i>\u7528\u4e8e\u96be\u6cbb\u6027\u764c\u75c7\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff1b\u4ee5\u53ca HFG1\uff0c\u4e00\u79cd\u7528\u4e8e\u8868\u8fbe GLP-1R \u6fc0\u52a8\u5242\u7684 LNP-mRNA \u590d\u5408\u7269\uff0c\u7528\u4e8e\u51cf\u80a5\u548c\u6cbb\u7597\u7cd6\u5c3f\u75c5\u3002\u66f4\u591a\u4fe1\u606f\u8bf7\u8bbf\u95ee\u00a0https:\/\/highfieldbio.com\/<\/a>.<\/p><\/div>

\u8054\u7cfb\u65b9\u5f0f<\/h2>

\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a
\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89
Opus \u751f\u7269\u6280\u672f\u901a\u8baf
danieleramian@comcast.net<\/a>
425-306-8716<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

HighField Biopharmaceuticals \u5728\u4e2d\u56fd\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\uff0c\u7528\u4e8e\u5176\u72ec\u7279\u7684 TRAFsomeTM T \u7ec6\u80de\u63a5\u5408\u5242 (HF50) \u6cbb\u7597\u5b9e\u4f53\u7624\u764c\u75c7 HF50 \u7684 1 \u671f\u8bd5\u9a8c\u9884\u8ba1\u5c06\u4e8e 2025 \u5e74 1 \u5b63\u5ea6\u5f00\u59cb\uff0c\u4ee5\u8bc4\u4f30\u5176\u5728\u665a\u671f\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u7279\u5f81\u3001\u514d\u75ab\u539f\u6027\u548c\u521d\u6b65\u7597\u6548\u3002HF50 \u662f [\u2026]<\/p>","protected":false},"author":1,"featured_media":7493,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"\nHighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors\u00a0is expected to begin in 1Q2025. HF50 is part […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-18T14:01:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-18T14:07:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PJWCreative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\"},\"author\":{\"name\":\"PJWCreative\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\"},\"headline\":\"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers\",\"datePublished\":\"2024-12-18T14:01:50+00:00\",\"dateModified\":\"2024-12-18T14:07:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\"},\"wordCount\":636,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\",\"url\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\",\"name\":\"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg\",\"datePublished\":\"2024-12-18T14:01:50+00:00\",\"dateModified\":\"2024-12-18T14:07:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\",\"name\":\"PJWCreative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"caption\":\"PJWCreative\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals \u5728\u4e2d\u56fd\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\uff0c\u5f00\u5c55\u5176\u72ec\u7279\u7684 TRAFsomeTM T \u7ec6\u80de\u8854\u63a5\u5242 (HF50) \u7528\u4e8e\u6cbb\u7597\u5b9e\u4f53\u7624\u7684\u4e34\u5e8a\u8bd5\u9a8c - HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/","og_locale":"zh_CN","og_type":"article","og_title":"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers - HighField Biopharmaceuticals","og_description":"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers A Phase 1 trial of HF50 to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity, and preliminary efficacy in patients with advanced solid tumors\u00a0is expected to begin in 1Q2025. HF50 is part […]","og_url":"https:\/\/highfieldbio.com\/zh\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2024-12-18T14:01:50+00:00","article_modified_time":"2024-12-18T14:07:43+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg","type":"image\/jpeg"}],"author":"PJWCreative","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/"},"author":{"name":"PJWCreative","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0"},"headline":"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers","datePublished":"2024-12-18T14:01:50+00:00","dateModified":"2024-12-18T14:07:43+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/"},"wordCount":636,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/","url":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/","name":"HighField Biopharmaceuticals \u5728\u4e2d\u56fd\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\uff0c\u5f00\u5c55\u5176\u72ec\u7279\u7684 TRAFsomeTM T \u7ec6\u80de\u8854\u63a5\u5242 (HF50) \u7528\u4e8e\u6cbb\u7597\u5b9e\u4f53\u7624\u7684\u4e34\u5e8a\u8bd5\u9a8c - HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg","datePublished":"2024-12-18T14:01:50+00:00","dateModified":"2024-12-18T14:07:43+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2024\/12\/HIGHIELD_LinkedIn-IND_HF50_China.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2024\/12\/18\/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-unique-trafsometm-t-cell-engager-hf50-to-treat-solid-tumor-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM\u00a0T Cell Engager (HF50) To Treat Solid Tumor Cancers"}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0","name":"PJW\u521b\u610f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","caption":"PJWCreative"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7485"}],"version-history":[{"count":7,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7485\/revisions"}],"predecessor-version":[{"id":7492,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7485\/revisions\/7492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7493"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7485"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}